5 results about "Prion Proteins" patented technology

Provided herein is a nucleic acid encoding a prion protein, wherein the prion protein (a) comprises an amino acid sequence comprising a protective sequence variant such as a G127V mutation and (b) lacks a fully functional 3' glycosylphosphatidylinositol (GPI)-anchor attachment sequence. Also provided are viral vectors and pharmaceutical compositions comprising the nucleic acids. Further provided are methods and uses of treating prion diseases or other neurodegenerative diseases that confer toxicity through cell surface- anchored prion proteins in a subject, comprising administering to the subject an effective amount of a pharmaceutical composition or viral vector described herein.

The invention discloses an RNA co-immunoprecipitation kit for specific binding of prion protein in muscle cells and an RNA extraction method, and relates to the technical field of bioengineering. According to the present invention, the specific co-precipitation kit preparation and the specific extraction steps comprise cell lysis, cell lysis solution-antibody-magnetic bead incubation, protein digestion and RNA extraction, such that the high purity and the sufficient amount of the enriched RNA are successfully ensured so as to completely meet the strict requirements of the subsequent RNA-seq sequencing. The method overcomes the inherent defects of the existing RIP technology in the research of non-classical RNA binding proteins, realizes the optimization of the whole process from high-specificity enrichment to high-quality sequencing sample preparation through the integrated innovation of methodology and the kit, has the outstanding advantages of strong specificity, high sensitivity, good repeatability, simple operation and the like, and has a wide application prospect in the research of non-classical RNA binding proteins. And remarkable technical progress is achieved, and a positive application effect is generated.

Provided are RNAi agents, pharmaceutical compositions, and methods for reducing the amount or activity of PRNP RNA in a cell or a subject, and in certain instances reducing the amount of prion protein in a cell or a subject. Such RNAi agents, pharmaceutical compositions, and methods are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such neurodegenerative diseases include prion diseases, such as Creutzfeldt-Jakob disease (CJD) (e.g., variant Creutzfeldt-Jakob Disease (vCJD), classic Creutzfeldt-Jakob Disease (cCJD), familial Creutzfeldt-Jakob Disease (fCJD), or sporadic Creutzfeldt-Jakob Disease (sCJD)), Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, or kuru; synucleinopathies such as Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies; or tauopathies such as frontal temporal dementia associated with a Tau mutation, Pick's disease, progressive supranuclear palsy, corticobasal neurodegeneration, or chronic traumatic encephalopathy (CTE).

The application discloses a tumor marker for colorectal cancer diagnosis and a nucleic acid aptamer-based detection method, relates to a nucleic acid aptamer sequence for specifically recognizing epithelial cell adhesion molecule (EpCAM) and prion protein (PRNP), EpCAM and PRNP proteins as colorectal cancer diagnosis markers and a method for detecting expression levels in exosomes. The nucleic acid aptamer sequence is obtained by screening a cell-SELEX (systematic evolution of ligands by exponential enrichment) technology with colorectal cancer cells as targets, can be chemically synthesized in vitro, is stable in structure, easy to modify and replace, low in cost and high in reproducibility; and the target protein is highly enriched in exosomes derived from colorectal cancer tumor cells and can be used as a colorectal cancer diagnosis marker. The nucleic acid aptamer obtained by the application can be applied to imaging of human colorectal cancer related malignant tumor cells and derived exosomes, preparation of coupled drugs, clinical diagnosis and development of related kits.

The present invention is directed to a novel therapeutic strategy for treating a disease mediated by copper, by inhibiting the function of cellular prion protein (PrP).